ORI
LIVE

Serial Number

90757832

Owner

Oribiotech Limited

Attorney

Howard J. Shire

Filing Date

Jun 7, 2021

Add to watchlist:

No watchlists yet
View on USPTO

ORI Trademark

Serial Number: 90757832 • Registration: 7117661

ORI is a trademark filed by Oribiotech Limited on June 7, 2021. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Oribiotech Limited (12 trademarks)

First Floor, 3 Cumbrian House,

Entity Type: 99

Trademark Details

Filing Date

June 7, 2021

Registration Date

July 25, 2023

Published for Opposition

May 9, 2023

Goods & Services

downloadable computer software platforms for controlling, monitoring, programming, communicating with, operating and adjusting apparatus and equipment in the fields of cell culturing, cell therapy, and gene therapy; downloadable computer software platforms for monitoring environmental conditions within buildings, apparatuses and equipment, and for controlling, programming and adjusting devices within a building, facility, grounds, and designated spatial area that control environmental conditions, in the fields of cell culturing, cell therapy and gene therapy; downloadable computer software platforms for collecting and storing data in the fields of cell culturing, cell therapy and gene therapy; downloadable computer software platforms for monitoring patient health, downloadable computer software platforms for providing information in the fields of cell culturing, cell therapy and gene therapy

Software as a service (SaaS) services featuring software for controlling, monitoring, programming, communicating with, operating and adjusting apparatus and equipment in the fields of cell culture, cell therapy and gene therapy; Providing temporary use of on-line non-downloadable computer software for controlling, monitoring, programming, communicating with, operating and adjusting apparatus and equipment in the fields of cell culture, cell therapy and gene therapy; Platform as a service (PAAS) featuring computer software platforms for controlling, monitoring, programming, communicating with, operating and adjusting apparatus and equipment in the fields of cell culturing, cell therapy and gene therapy; Software as a service (SAAS) services featuring software for monitoring environmental conditions within cell culturing containers and bioreactors and controlling, programming and adjusting devices within a cell culturing container, bioreactor and designated spatial area that controls environmental conditions, in the fields of cell culturing, cell therapy and gene therapy; Providing temporary use of on-line non-downloadable computer software for monitoring environmental conditions within cell culturing containers and bioreactors and controlling, programming and adjusting devices within a cell culturing container, bioreactor and designated spatial area that controls environmental conditions, in the fields of cell culturing, cell therapy and gene therapy; Platform as a service (PAAS) featuring computer software platforms for monitoring environmental conditions within cell culturing containers and bioreactors and controlling, programming and adjusting devices within a cell culturing container, bioreactor and designated spatial area that controls environmental conditions, in the fields of cell culturing, cell therapy and gene therapy; Software as a service (SAAS) services featuring software for collecting and storing of data in the fields of cell culturing, cell therapy and gene therapy; Platform as a service (PAAS) featuring software for collecting and storing of data in the fields of cell culturing, cell therapy and gene therapy; Software as a service (SaaS) services featuring software for monitoring patient health; Software as a service (SaaS) services featuring software for providing information in the fields of cell culture, cell therapy and gene therapy; Providing temporary use of on-line non-downloadable computer software for providing information in the fields of cell culturing, cell therapy and gene therapy; Platform as a service (PAAS) featuring computer software platforms for providing information in the fields of cell culturing, cell therapy and gene therapy; design and development of scientific equipment and apparatus in the fields of cell culturing, cell therapy and gene therapy; design and development of cell culturing, cell therapy and gene therapy manufacturing equipment, manufacturing systems and manufacturing processes for others; development of cell culturing, cell therapy and gene therapy processes for others; rental and leasing of scientific apparatus and equipment for cell culturing, cell therapy and gene therapy

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 16, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jan 16, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 16, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 16, 2025 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 11, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jan 11, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 11, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 11, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 11, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 11, 2024 COAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 25, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 25, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 9, 2023 NPUB
PUBLISHED FOR OPPOSITION
May 9, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 19, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 5, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 5, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 5, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 5, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 5, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 15, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 15, 2023 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 14, 2023 ERFR
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Dec 14, 2022 ASCK
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 14, 2022 GNFN
FINAL REFUSAL E-MAILED
Oct 14, 2022 GNFR
FINAL REFUSAL WRITTEN
Oct 14, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 20, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 20, 2022 CRFA
ASSIGNED TO LIE
Sep 19, 2022 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 15, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 14, 2022 GNRN
NON-FINAL ACTION E-MAILED
Feb 14, 2022 GNRT
NON-FINAL ACTION WRITTEN
Feb 14, 2022 CNRT
ASSIGNED TO EXAMINER
Feb 7, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 27, 2021 NWOS
NEW APPLICATION ENTERED
Jun 10, 2021 NWAP